| Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) SPL Travis, D Schnell, P Krzeski, MT Abreu, DG Altman, JF Colombel, ... Gut 61 (4), 535-542, 2012 | 659 | 2012 |
| A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease BR Yacyshyn, MB Bowen-Yacyshyn, L Jewell, JA Tami, CF Bennett, ... Gastroenterology 114 (6), 1133-1142, 1998 | 472 | 1998 |
| Reliability and initial validation of the ulcerative colitis endoscopic index of severity SPL Travis, D Schnell, P Krzeski, MT Abreu, DG Altman, JF Colombel, ... Gastroenterology 145 (5), 987-995, 2013 | 450 | 2013 |
| Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active … BR Yacyshyn, WY Chey, J Goff, B Salzberg, R Baerg, AL Buchman, ... Gut 51 (1), 30-36, 2002 | 275 | 2002 |
| Canonical Wnt signaling ameliorates aging of intestinal stem cells K Nalapareddy, KJ Nattamai, RS Kumar, R Karns, ... Cell reports 18 (11), 2608-2621, 2017 | 201 | 2017 |
| Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence DN Gerding, CP Kelly, G Rahav, C Lee, ER Dubberke, PN Kumar, ... Clinical infectious diseases 67 (5), 649-656, 2018 | 189 | 2018 |
| Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the … SB Hanauer, WJ Sandborn, C Dallaire, A Archambault, B Yacyshyn, ... Canadian Journal of Gastroenterology and Hepatology 21, 827-834, 2007 | 187 | 2007 |
| Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis WJ Sandborn, L Peyrin-Biroulet, J Zhang, M Chiorean, S Vermeire, ... Gastroenterology 158 (3), 550-561, 2020 | 185 | 2020 |
| Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis WJ Sandborn, J Regula, BG Feagan, E Belousova, N Jojic, M Lukas, ... Gastroenterology 137 (6), 1934-1943. e3, 2009 | 185 | 2009 |
| A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease JD Lewis, RS Sandler, C Brotherton, C Brensinger, H Li, MD Kappelman, ... Gastroenterology 161 (3), 837-852. e9, 2021 | 174 | 2021 |
| The clinical importance of proton pump inhibitor pharmacokinetics BR Yacyshyn, ABR Thomson Digestion 66 (2), 67-78, 2002 | 171 | 2002 |
| Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability B Yacyshyn, J Meddings, D Sadowski, MB Bowen-Yacyshyn Digestive diseases and sciences 41, 2493-2498, 1996 | 154 | 1996 |
| Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non … RJ Vickers, GS Tillotson, R Nathan, S Hazan, J Pullman, C Lucasti, ... The Lancet infectious diseases 17 (7), 735-744, 2017 | 140 | 2017 |
| Human Clostridium difficile infection: altered mucus production and composition MA Engevik, MB Yacyshyn, KA Engevik, J Wang, B Darien, DJ Hassett, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (6 …, 2015 | 138 | 2015 |
| A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active … B Yacyshyn, WY Chey, MK Wedel, ZY Rosie, D Paul, E Chuang Clinical Gastroenterology and Hepatology 5 (2), 215-220, 2007 | 136 | 2007 |
| Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT) P Lee, BR Yacyshyn, MB Yacyshyn Diabetes, Obesity and Metabolism 21 (3), 479-490, 2019 | 129 | 2019 |
| CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability BR Yacyshyn, JB Meddings Gastroenterology 108 (1), 132-137, 1995 | 127 | 1995 |
| Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile MA Engevik, KA Engevik, MB Yacyshyn, J Wang, DJ Hassett, B Darien, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (6 …, 2015 | 110 | 2015 |
| Beta 1 integrin (CD29) expression on human postnatal T cell subsets defined by selective CD45 isoform expression. LM Pilarski, BR Yacyshyn, GS Jensen, E Pruski, HF Pabst Journal of immunology (Baltimore, Md.: 1950) 147 (3), 830-837, 1991 | 96 | 1991 |
| Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide)(ISIS 2302) in active Crohn's disease BR Yacyshyn, C Barish, J Goff, D Dalke, M Gaspari, R Yu, J Tami, FA Dorr, ... Alimentary pharmacology & therapeutics 16 (10), 1761-1770, 2002 | 82 | 2002 |
William SandbornUniversity of California San DiegoVerified email at ucsd.edu
